@article{ref1,
title="Efficacy of asenapine in schizophrenia resistant to clozapine combined with electroconvulsive therapy: A case report",
journal="Clinical psychopharmacology and neuroscience",
year="2019",
author="Ochi, S. and Inoue, S. and Yoshino, Y. and Shimizu, H. and Iga, J.-i. and Ueno, S.-i.",
volume="17",
number="4",
pages="559-563",
abstract="Schizophrenic patients resistant to antipsychotics are diagnosed as having treatment-refractory schizophrenia, and they are treated with clozapine. However, clozapine is sometimes combined with electroconvulsive therapy (ECT) if clozapine monotherapy fails. In this report, a severe treatment-refractory schizophrenic patient who did not respond to clozapine even with ECT, but who recovered with asenapine monotherapy, is presented. Asenapine, considered a serotonin spectrum dopamine modulator, is a new atypical antipsychotic with unique pharmacological features that is used not only for schizophrenia, but also for bipolar disorder. The unique features of asenapine may be effective for some treatment-refractory schizophrenic patients. © 2019, Korean College of Neuropsychopharmacology.<p /><p>Language: en</p>",
language="en",
issn="1738-1088",
doi="10.9758/cpn.2019.17.4.559",
url="http://dx.doi.org/10.9758/cpn.2019.17.4.559"
}